{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:48:21Z","timestamp":1794354501708,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ygyno.2021.10.069","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T18:48:46Z","timestamp":1634842126000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Madhavi","family":"Manyam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Kennard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.10.069_bb0005","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2407-11-451","article-title":"Permissivity of the NCI-60 cancer cell lines to oncolytic vaccinia virus GLV-1h68","volume":"11","author":"Ascierto","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2021.10.069_bb0015","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00262-009-0686-7","article-title":"The immunologic aspects of poxvirus oncolytic therapy","volume":"58","author":"Worschech","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ygyno.2021.10.069_bb0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12967-016-1096-1","article-title":"Colonization of xenograft tumors by oncolytic vaccinia virus (VACV) results in enhanced tumor killing due to the involvement of myeloid cells","volume":"14","author":"Kilinc","year":"2016","journal-title":"J. Transl. Med."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2021.10.069_bb0025","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/jco.2013.31.15_suppl.3062","article-title":"Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging (NCT009794131)","volume":"31","author":"Khan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0030","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-3232","article-title":"Phase I trial of intravenous oncolytic vaccinia virus (Olvi-Vec) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma","volume":"23","author":"Mell","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0035","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"15","author":"Lauer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2010.10.031","article-title":"Oncolytic virotherapy of gynecologic malignancies","volume":"120","author":"Hartkopf","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-0031-1298281","article-title":"Oncolytic viruses to treat ovarian cancer patients - a review of results from clinical trials","volume":"72","author":"Hartkopf","year":"2012","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0050","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.mt.6300221","article-title":"Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus","volume":"15","author":"Song","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0055","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2174\/138920112800958850","article-title":"Bugs and drugs: oncolytic virotherapy in combination with chemotherapy","volume":"13","author":"Wennier","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.10.069_bb0060","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00432-014-1799-8","article-title":"Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer","volume":"141","author":"Ikeya","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0075","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11888-010-0069-7","article-title":"Circulating tumor cells and colorectal cancer","volume":"6","author":"Allen","year":"2010","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-62703-727-3_5","article-title":"Immunologic monitoring of cancer vaccine trials using the ELISPOT assay","volume":"1102","author":"Butterfield","year":"2014","journal-title":"Meth. Mol. Biol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0085","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0090","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.10.069_bb0095","article-title":"Heating it up: oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nbt937","article-title":"Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins","volume":"22","author":"Yu","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00438-009-0475-1","article-title":"The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation","volume":"282","author":"Zhang","year":"2009","journal-title":"Mol. Genet. Genomics"},{"key":"10.1016\/j.ygyno.2021.10.069_bb0110","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0115","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: past, present, and future","volume":"118","author":"Parrino","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.10.069_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011400","article-title":"Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model","volume":"5","author":"N\u00f6rder","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2021.10.069_bb0125","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0130","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/cancers3033114","article-title":"Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines","volume":"3","author":"Weir","year":"2011","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/gt.2010.121","article-title":"Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1","volume":"18","author":"Huang","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.it.2017.07.013","article-title":"cGAS-STING and Cancer: dichotomous roles in tumor immunity and development","volume":"39","author":"Ng","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0150","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T-cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12307-014-0160-8","article-title":"Immune effects of bevacizumab: killing two birds with one stone","volume":"8","author":"Elamin","year":"2015","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.ygyno.2021.10.069_bb0160","first-page":"A9","article-title":"Oncolytic vaccinia (Olvi-Vec) primed immunochemotherapy in platinum-resistant\/ refractory ovarian cancer","volume":"30","author":"Holloway","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"54","key":"10.1016\/j.ygyno.2021.10.069_bb0165","doi-asserted-by":"crossref","first-page":"S628","DOI":"10.1016\/j.annonc.2020.08.976","volume":"31","author":"Holloway","year":"2020","journal-title":"Ann. Oncol."}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2022.02.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821015134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821015134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:33:56Z","timestamp":1672752836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821015134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0090825821015134"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.069","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}